Study Links Genetic Variation to Possible Protection Against Sudden Cardiac Arrest
|
Tweet
|
|
Physician-scientists at the Cedars-Sinai Heart Institute have found that a genetic variation is associated with lower risk of sudden cardiac arrest, a disorder that gives little warning and is fatal in about 95 percent of cases. Findings will be published tomorrow by the Public Library of Science (PloS One).
The discovery came from a genome-wide association study, which examines the entire set of human genes to detect possible links between genetic variations and specific conditions or diseases. In this study, the Cedars-Sinai Heart Institute researchers compared the genetic makeup of 424 subjects who had experienced sudden cardiac arrest to the DNA of 226 control subjects who had no history of the disorder. All patients had a history of coronary artery disease, which commonly underlies sudden cardiac arrest.
Based on a comparison of the two groups, a genetic variation at the location of the GPC5 gene – a genetic sequence called rs3864180 – was found to be associated with a reduced risk of sudden cardiac arrest.
“If you have this genetic variation in your DNA, it appears that you may have a 15 percent lower likelihood of sudden cardiac arrest,” said Sumeet S. Chugh, M.D., associate director of the Cedars-Sinai Heart Institute, holder of The Pauline and Harold Price Chair in Cardiac Electrophysiology Research, and one of the senior authors of the study.
“This kind of genetic analysis is not aimed at identifying a single big gene defect or mutation,” he said. “The goal is to identify a series of smaller novel gene defects that, when grouped together, collectively result in either a protective effect or an increased susceptibility to sudden cardiac arrest.”
Chugh leads the Oregon Sudden Unexpected Death Study, a comprehensive, 16-hospital, multi-year assessment of cardiac deaths in the 1 million population Portland, Ore. metropolitan area. Funded in part by the National Heart Lung and Blood Institute, the study’s goal is to shed light on the risk factors, triggers and genetic defects associated with sudden cardiac death.
All patients in the genome-wide study were part of the Oregon Sudden Unexpected Death Study. Subjects included both survivors and deceased victims of sudden cardiac arrest, but excluded individuals who had a chronic terminal illness or were known to have died suddenly from non-cardiac-related causes related to trauma, overdose, drowning or suicide.
The authors note that while the protective variant rs3864180 occurs within the GPC5 gene, their results do not definitively prove that the gene itself is involved in sudden cardiac death risk. It is possible, for example, that rs386410 modifies the actions of a different gene or is in proximity to another gene of interest.
Genome-wide association studies are intended to identify regions of the human genome that are associated with development of specific diseases. The GPC5 gene encodes glypican 5, one of the six members of the heparan sulfate proteoglycan (HSPG) family. In the cardiovascular system, cell surfaces and surrounding supportive material express large amounts of these proteins, which are involved in a wide variety of critical cell functions. Additional study of rs3864180 and other variations of the GPC5 gene may lead to a better understanding of the mechanisms leading to sudden cardiac arrest.
Unlike heart attacks (myocardial infarction), which are typically caused by clogged coronary arteries reducing blood flow to the heart muscle, sudden cardiac arrest is the result of defective electrical impulses. Patients may have little or no warning, and the disorder usually causes nearly instantaneous death. Every year, 250,000 to 300,000 people in the U.S. and up to 5 million worldwide die from sudden cardiac arrest.
Despite years of significant advances in emergency medicine and resuscitation, just five percent of those who suffer sudden cardiac arrest survive. For patients at known risk for this or other heart rhythm abnormalities, an implantable cardioverter-defibrillator (ICD) may be placed in the chest or abdomen to detect faulty electrical impulses and provide a shock to return normal rhythm. Better genetic predictors of risk may someday enable the accurate prediction of which patients are most likely to benefit from costly ICD therapy.
The genome-wide study was a collaborative effort of scientists from Cedars-Sinai Heart Institute, Johns Hopkins University School of Medicine; Oregon Health and Science University; Wake Forest University; University of Texas Health Science Center; University of Washington, and Group Health Research Institute of Seattle, Wash.;
The Cedars-Sinai Heart Institute is internationally recognized for outstanding heart care built on decades of innovation and leading-edge research. From cardiac imaging and advanced diagnostics to surgical repair of complex heart problems to the training of the heart specialists of tomorrow and research that is deepening medical knowledge and practice, the Cedars-Sinai Heart Institute is known around the world for excellence and innovations.
---
Source: Cedars-Sinai Medical Center
 |
 |
 |
 | ||
| RELATED STORIES: | ||
| Comments | [ + Post Your Own ] |
Now you're in the public comment zone. What follows is not Armenian Medical Network's stuff; it comes from other people and we don't vouch for it. A reminder: By using this Web site you agree to accept our Terms of Service. Click here to read the Rules of Engagement.
There are no comments for this entry yet. [ + Comment here + ]
We are pleased to let readers post comments about an article. Please increase the credibility of your post by including your full name and email.
All comments are reviewed by our editors before they are posted on the site. Just keep it clean, kids.
